Tenaya Therapeutics, Inc.

NasdaqGS:TNYA 주식 보고서

시가총액: US$243.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Tenaya Therapeutics 관리

관리 기준 확인 3/4

Tenaya Therapeutics' CEO는 Faraz Ali, Jun2018 에 임명되었습니다 의 임기는 6.08 년입니다. 총 연간 보상은 $ 2.89M, 20.5% 로 구성됩니다. 20.5% 급여 및 79.5% 보너스(회사 주식 및 옵션 포함). 는 $ 59.93K 가치에 해당하는 회사 주식의 0.025% 직접 소유합니다. 59.93K. 경영진과 이사회의 평균 재임 기간은 각각 5.6 년과 7.8 년입니다.

주요 정보

Faraz Ali

최고 경영자

US$2.9m

총 보상

CEO 급여 비율20.5%
CEO 임기6.1yrs
CEO 소유권0.02%
경영진 평균 재임 기간5.6yrs
이사회 평균 재임 기간7.8yrs

최근 관리 업데이트

Recent updates

We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Jun 04
We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Dec 20
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Mar 07
Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Dec 06
Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment

Sep 06

Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07

Aug 10

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Nov 01
Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms

Aug 06

CEO 보상 분석

Faraz Ali 의 보수는 Tenaya Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$3mUS$594k

-US$124m

Sep 30 2023n/an/a

-US$128m

Jun 30 2023n/an/a

-US$129m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$6mUS$571k

-US$124m

Sep 30 2022n/an/a

-US$116m

Jun 30 2022n/an/a

-US$104m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$5mUS$494k

-US$73m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$49m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020US$750kUS$425k

-US$38m

보상 대 시장: Faraz 의 총 보상 ($USD 2.89M )은 US 시장( $USD 1.62M ).

보상과 수익: Faraz 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Faraz Ali (51 yo)

6.1yrs

테뉴어

US$2,890,062

보상

Mr. Faraz Ali, M.B.A., serves as Chief Executive Officer since June 2018 & Director since September 2018 at Tenaya Therapeutics, Inc. and served as its Secretary since June 2018. Mr. Ali served as Chief Bu...


리더십 팀

이름위치테뉴어보상소유권
Faraz Ali
CEO & Director6.1yrsUS$2.89m0.025%
$ 59.9k
Deepak Srivastava
Scientific Founderno dataUS$280.39k0.72%
$ 1.7m
Leone Patterson
Chief Financial & Business Officer3.1yrsUS$1.27m0.026%
$ 64.3k
Whittemore Tingley
Chief Medical Officer5.6yrsUS$1.38m0.032%
$ 76.8k
Eric Olson
Scientific Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Bruce Conklin
Scientific Founderno data데이터 없음데이터 없음
Saptarsi Haldar
Scientific Founderno data데이터 없음데이터 없음
Sheng Ding
Scientific Founderno data데이터 없음데이터 없음
Benoit Bruneau
Scientific Founderno data데이터 없음데이터 없음
Kee-Hong Kim
Chief Technology Officer2.3yrs데이터 없음데이터 없음
Timothy Hoey
Chief Scientific Officer6.9yrsUS$2.56m0.25%
$ 605.6k
Michelle Corral
Vice President of Investor Relationship & Corporate Communicationsno data데이터 없음데이터 없음

5.6yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: TNYA 의 관리팀은 노련하고 경험 (평균 재직 기간 5.5 년)입니다.


이사회 구성원

이름위치테뉴어보상소유권
Faraz Ali
CEO & Director6.1yrsUS$2.89m0.025%
$ 59.9k
Deepak Srivastava
Scientific Founder7.8yrsUS$280.39k0.72%
$ 1.7m
Eric Olson
Scientific Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
David Goeddel
Independent Chairman of the Board7.9yrsUS$228.89k데이터 없음
Jin-Long Chen
Independent Director7.8yrsUS$198.89k0.032%
$ 77.5k
Mark Kay
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Jeffrey Walsh
Independent Director4.3yrsUS$214.89k0%
$ 0
Douglas Mann
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
R. Williams
Independent Director7.8yrsUS$207.39k0.038%
$ 93.0k
Jonathan Weissman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Elizabeth McNally
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Catherine Stehman-Breen
Independent Director4.1yrsUS$202.39k0.010%
$ 25.2k

7.8yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: TNYA 의 이사회경험(평균 재직 기간 7.7 년)으로 간주됩니다.